TERT and non-small cell lung carcinoma: Vx-001 targets TERT (TElomerase Reverse Transcriptase) and has been tested in a basket phase 1/2 clinical study on patients with different tumour types, mainly non-small cell lung cancer (NSCLC) and breast cancer; Vx-001 has been shown to be strongly immunogenic, with some objective clinical responses and significantly better overall survival in patients who developed a vaccine-specific immune response and, especially, in patients with pre-treated metastatic NSCLC.10–14